Novartis
Breakthrough therapy designation for Novartis in advanced breast cancer treatment
August 3, 2016Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib
Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …
Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends
July 25, 2016Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler
Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …
Novartis lowers core operating profit outlook in Q2 results
July 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results
Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote
July 14, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …
New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile
July 7, 2016Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars
Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …
Novartis signs $150 million deal with Xencor to develop bispecific antibodies
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial
Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …
Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study
June 23, 2016Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
Nice backs two cancer drugs from Novartis
June 22, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
Novartis aims to launch five major global biosimilars by 2020
June 21, 2016Manufacturing and Production, Research and Development 2020, Novartis, Sandoz, biosimilars
Novartis (VTX: NOVN) has announced plans to triple its biosimilar portfolio by 2020, with the launch of five major biosimilar …
Novartis says to develop antimalarial treatment with Medicines for Malaria Venture
June 15, 2016Research and Development, Sales and Marketing Novartis, antimalarial drug, drug trial
Swiss pharma major Novartis (NYSE: NVS) said it has partnered with Medicines for Malaria Venture (MMV) and the Bill & Melinda …
Novartis presents strong results in rare blood disorder trials
June 10, 2016Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
Novartis to compare Cosentyx with Humira in new clinical trials
June 8, 2016Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016
Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
Latest content
FibroFind appoints Lee Borthwick as CEO
